March 27, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
| Attention: | Joshua Gorsky |
| Re: | Tenaya Therapeutics, Inc. |
Registration Statement on Form S-3
Filed March 21, 2025
File No. 333-286005
Acceleration Request
Requested Date: March 31, 2025
Requested Time: 4:00 P.M. Eastern Time, or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tenaya Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-286005) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041.
Please direct any questions or comments regarding this acceleration request to Jennifer Knapp at (650) 849-3041.
[Signature page follows]
Securities and Exchange Commission
March 27, 2025
Page 2
| Sincerely, |
| TENAYA THERAPEUTICS, INC. |
| /s/ Faraz Ali, M.B.A. |
| Faraz Ali, M.B.A. |
| Chief Executive Officer |
| cc: | Jennifer Drimmer Rokovich, J.D., Tenaya Therapeutics, Inc. |
Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C.
Emily A. Coskey, Wilson Sonsini Goodrich & Rosati, P.C.